Aviva’s PTC Therapeutics PTCT Stock Holding History

Aviva’s Portfolio PTCT Stock Details PTCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-6,764	Closed	-$461K	–	897
2026 Q1	$461K	Buy	6,764 +2,417	+56%	+$171K	﹤0.01%	719
2025 Q4	$330K	Sell	4,347 -4,285	-50%	-$311K	﹤0.01%	848
2025 Q3	$530K	Sell	8,632 -925	-10%	-$48.2K	﹤0.01%	711
2025 Q2	$467K	Buy	+9,557	New	+$454K	﹤0.01%	796

Other funds holding PTCT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Aviva's PTCT Position: Q2 2026 in Review

Aviva sold out of PTC Therapeutics (PTCT) in Q2 2026, closing a stake of 6,764 shares — an estimated $461K sold.

Aviva first reported a position in PTCT in Q2 2025 and held it in 4 quarters. The position peaked at $530K in Q3 2025. 382 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.

Aviva reported no remaining PTC Therapeutics position as of Q2 2026 after selling out during the quarter.
Aviva sold 6,764 PTC Therapeutics shares in Q2 2026, an estimated $461K.
Aviva first reported a position in PTC Therapeutics in Q2 2025 and held it in 4 quarters.
Aviva's PTC Therapeutics position peaked at $530K in Q3 2025.
382 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.

Based on Aviva's 13F filing for Q2 2026, filed 13 Aug 2026.